13300-09-9

Basic information

• Product Name: 4-methyl-6-phenylpyridazin-3(2H)-one
• Synonyms: 4-methyl-6-phenylpyridazin-3(2H)-one;4-Methyl-6-phenyl-2,3-dihydropyridazine-3-one;4-Methyl-6-phenyl-3(2H)-pyridazinone;Einecs 236-322-5;4-methyl-6-phenylpyridazine-3(2H)-one;5-methyl-3-phenyl-1H-pyridazin-6-one;4-Methyl-6-phenyl-2H-pyridazin-3-one
• CAS NO: 13300-09-9
• Molecular Formula: C₁₁H₁₀N₂O
• Molecular Weight: 186.2099
• EINECS: 236-322-5
• Mol File: 13300-09-9.mol
• Article Data: 18

Chemical Properties

• Appearance: /
• Density: 1.17 g/cm³
• Refractive Index: 1.609
• CAS DataBase Reference: 4-methyl-6-phenylpyridazin-3(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-methyl-6-phenylpyridazin-3(2H)-one(13300-09-9)
• EPA Substance Registry System: 4-methyl-6-phenylpyridazin-3(2H)-one(13300-09-9)

Safety Data

• Hazardous Substances Data: 13300-09-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-methyl-6-phenylpyridazin-3(2H)-one is used as a pharmaceutical compound for its potential medicinal properties. Its unique structure and properties make it an interesting target for research and development in the field of medicine.
Used in Agrochemical Industry:
4-methyl-6-phenylpyridazin-3(2H)-one is used as an agrochemical compound due to its potential applications in this field. Its unique structure and properties may contribute to the development of new agrochemical products.
Used in Organic Synthesis:
4-methyl-6-phenylpyridazin-3(2H)-one is used as a building block in organic synthesis for the preparation of various other compounds. Its unique structure allows it to be a valuable component in the synthesis of a wide range of organic compounds.
Used in Research and Development:
4-methyl-6-phenylpyridazin-3(2H)-one is used as a subject of research and development due to its potential biological activity and medicinal properties. Further studies on this compound may lead to the discovery of new applications and advancements in various industries.

InChI:InChI=1/C11H10N2O/c1-8-7-10(12-13-11(8)14)9-5-3-2-4-6-9/h2-7H,1H3,(H,13,14)

Upstream product

• 81819-89-8 3-Butoxy-4-methyl-6-phenyl-pyridazine 
• 98-80-6 phenylboronic acid 
• 52239-91-5 4-methyl-6-phenyl-4,5-dihydropyridazin-3(2H)-one 
• 50-00-0 formaldehyd 
• 266001-35-8 4-diethoxyphosphoryl-6-phenylpyridazin-3(2H)-one 
• 15732-75-9 3-benzoyl-2-methylenepropionic acid 
• 71-43-2 benzene 
• 28657-39-8 3-chloro-4-methyl-6-phenylpyridazine 
• 4578-42-1 3-methoxy-6-phenylpyridazine 
• 2170-03-8 itaconic acid anhydride 
• 5754-18-7 4-methyl-1,2-dihydropyridazine-3,6-dione 
• 1771-65-9 2-methyl-4-oxo-4-phenylbutanoic acid 
• 148903-67-7 β-benzoyl-2-methylenepropionic acid methyl ester 
• 13299-97-3 acide α-methyl β-benzoyl lactique 

Downstream Products

• 13299-75-7 4-methyl-2-(1-methyl-2-morpholin-4-yl-ethyl)-6-phenyl-2H-pyridazin-3-one 
• 105538-34-9 4-(5-Methyl-6-oxo-3-phenyl-6H-pyridazin-1-yl)-butyric acid ethyl ester 
• 157200-04-9 4-methyl-6-phenyl-3-trifluoromethanesulfonylpyridazine 
• 28657-39-8 3-chloro-4-methyl-6-phenylpyridazine 
• 90746-29-5 3-bromo-4-methyl-6-phenylpyridazine 
• 898820-55-8 3-bromo-4-(bromomethyl)-6-phenylpyridazine 
• 924909-75-1 TT-302 
• 30321-87-0 (5-methyl-6-oxo-3-phenyl-6H-pyridazin-1-yl)-acetic acid ethyl ester 
• 1450829-19-2 2-[5-methyl-6-oxo-3-phenylpyridazin-1(6H)-yl]acetic acid 
• 1450829-22-7 N-(1,3-benzodioxol-5-yl)-2-[5-methyl-6-oxo-3-phenylpyridazin-1(6H)-yl]acetamide 
• 1450829-21-6 N-(4-fluorophenyl)-2-[5-methyl-6-oxo-3-phenylpyridazin-1(6H)-yl]acetamide 
• 1450829-20-5 N-(4-bromophenyl)-2-[5-methyl-6-oxo-3-phenylpyridazin-1(6H)-yl]acetamide 
• 66573-63-5 8-methyl-6-phenyl-[1,2,4]triazolo[4,3-b]pyridazine 
• 32723-48-1 3-hydrazino-4-methyl-6-phenyl-pyridazine 

Relevant articles and documents

Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits

We report the development of a novel, aqueous-soluble, safe, small molecule, experimental therapeutic that suppresses injury-induced, proinflammatory cytokine increases in the brain, with resultant attenuation of synaptic protein biomarker loss and improvement in hippocampus-dependent behavioral deficits. A GMP production scheme for the active pharmaceutical ingredient, compound 17, is presented. The development and large-scale availability of this novel compound allow exploration of new, potentially disease-modifying, therapeutic approaches to CNS disorders.

FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS

The invention relates to chemical compounds, compositions and methods of making and using the same. In particular, the invention provides selected pyridazine compounds of the formula I are independently hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, sulfate, sulfenyl, sulfinyl, sulfonyl, sulfonate, sulfoxide, silyl, silyloxy, silylalkyl, silylthio, ═O, ═S, phosphonate, ureido, carboxyl, carbonyl, carbamoyl, or carboxamide; and X is optionally substituted pyrimidinyl or pyridazinyl, an isomer, a pharmaceutically acceptable salt, or derivative thereof. The invention additional relates to compositions comprising the compounds, and methods of using the compounds and compositions for modulation of cellular pathways, for treatment or prevention of inflammatory diseases, for research, drug screening, and therapeutic applications.

New, simple and versatile synthesis of 4,6-disubstituted pyridazin-3(2H)-ones

A simple, two-step synthesis of 4,6-disubstituted pyridazin-3(2H)-ones starting from 2-diethoxyphosphoryl-4-oxoalkanoates and hydrazines is described. The intermediate 4-diethoxyphosphoryl-4,5-dihydropyridazin-3(2H)-ones obtained in this way are used in a

Synthesis of regiospecifically polysubstituted pyridazinones

Desymmetrization of pyridazine-3,6-diones by the use of N-benzyl protective groups leads to useful starting materials for building polysubstituted pyridazine libraries in a regioselective manner.

COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS

The invention relates to compositions, conjugates and methods comprising pyridazine compounds and cholinesterase inhibitors for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.

COMPOSITIONS AND TREATMENTS FOR DEMYELINATING DISEASES AND PAIN DISORDERS

The invention relates to compositions and methods for treating patients with Demyelinating Diseases and Conditions including Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compositions and methods may also be used for Stroke Rehabilitation and the treatment of pain disorders including Neuropathic Pain and Chemokine-Induced Pain. The compositions comprise one or more pyridazine compounds having a pyridazinyl radical pendant with an aryl or substituted aryl, a heteroaryl or substituted heteroaryl.

SALTS OF PYRIDAZINE COMPOUNDS

The invention relates to stable and substantially purified synthetic pharmaceutically acceptable acid addition salts of pyridazine compounds of the formula I wherein R10 is hydrogen, hydroxyl, alkyl, alkoxy, alkenyl, alkynyl, alkylene, aryl, heteroaryl, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, =0, =S, carboxyl, carbonyl, carbamoyl, carboxamide, or phosphonate, and R11 is alkyl, alkoxy, alkenyl, alkynyl, alkylene, alkenylene, alkenyloxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, =0, =S, phosphonate, carboxyl, carbonyl, carbamoyl, carboxamide, or ureido. The invention also relates to formulations, dosage forms and compositions comprising the salts, and methods of using the salts, formulations, dosage forms and compositions.

COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND SECRETASES

The invention relates to compositions, conjugates and methods comprising pyridazine compounds and secretase inhibitors for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.

Bicyclic heterocycles as cannabinoid receptor modulators

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R3a, R4, A, B, n, Y and Z are described herein.

Sequential regio and chemoselective cross-coupling reactions by means of O6-tri-isopropylsulfonate of 4-bromo-pyridazine 3,6-dione

Regioselective desymmetrization of 4-substituted pyridazin-3,6-diones using sterically hindered 2,4,6-triisopropylphenyl-sulfonylchloride allowed efficient sequential palladium cross-coupling reactions.